Cite

HARVARD Citation

    Gauvreau, G. et al. (2023). Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma. European respiratory journal. 61 (3), p. . [Online]. 
  
Back to record